Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TETRACHEL vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Infections caused by susceptible strains of Rickettsiae,Mycoplasma pneumoniae infections,Psittacosis (ornithosis),Chlamydia trachomatis infections (e.g., uncomplicated urethral, endocervical, rectal),Brucellosis (in conjunction with streptomycin),Chancroid,Granuloma inguinale,Lymphogranuloma venereum,Relapsing fever,Bartonellosis,Plague,Tularemia,Acute intestinal amebiasis (adjunctive therapy),Severe acne,Propionibacterium acnes infections,Off-label: Helicobacter pylori eradication (as part of quadruple therapy)
Mild to moderate pain,Fever
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Tetracycline is primarily metabolized in the liver via glucuronidation and undergoes enterohepatic circulation. Minor metabolism may involve microsomal enzymes.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
65% (primarily albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
1.3 L/kg (extensive tissue penetration, including bone and teeth).
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 77-96% (decreased by food, dairy, antacids).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: 250 mg once daily. Cr Cl <30 m L/min: 125 mg once daily.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: 250 mg once daily. Child-Pugh C: 125 mg once daily.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children ≥8 years: 5 mg/kg orally once daily (max 500 mg) for 28 days.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at low end of dosing range; monitor renal function and adjust dose based on Cr Cl.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Tetracycline can cause fetal harm when administered to a pregnant woman. Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). It should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Photosensitivity: exaggerated sunburn reaction; avoid direct sunlight and UV light.,Hepatotoxicity: may cause liver damage, especially in patients with renal impairment or receiving high doses.,Renal impairment: accumulation may occur; dosage adjustment required.,Superinfection: use of tetracycline may result in overgrowth of non-susceptible organisms, including fungi.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea has been reported.,Intracranial hypertension: bulging fontanelles in infants and benign intracranial hypertension in adults.,Tissue irritation: avoid extravasation; thrombophlebitis risk with IV administration.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to tetracyclines or any component of the formulation.,Pregnancy (especially second and third trimesters) and lactation.,Children under 8 years of age (except for specific infections like anthrax or where no alternative exists).,Severe hepatic impairment.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid dairy products, calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum, as they reduce absorption. Iron supplements, bismuth subsalicylate, and zinc also chelate tetracyclines. Take tetracycline 1 hour before or 2 hours after meals. Avoid alcohol (hepatotoxicity risk).
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third trimesters (weeks 13 to 40) is associated with permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia in the child. Additionally, there is a risk of retarded skeletal growth and potentially reversible inhibition of bone growth. Use during the first trimester is generally discouraged unless no alternative therapy is available, as there may be a small risk of teratogenicity (e.g., neural tube defects, cardiovascular malformations) based on some observational studies, though evidence is conflicting.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Tetracycline is excreted into human milk, with milk-to-plasma ratio (M/P) approximately 0.5-0.8. Low levels of tetracycline are found in breast milk; however, due to potential for serious adverse reactions (e.g., permanent tooth discoloration and bone growth inhibition) in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profiles in lactation are preferred.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Due to physiological changes in pregnancy (increased plasma volume, increased renal clearance), tetracycline may achieve lower serum concentrations. However, specific dosing adjustment guidelines for tetracycline in pregnancy are not established. The drug is generally avoided in pregnancy, particularly after the first trimester. If use is necessary in the first trimester, standard dosing based on non-pregnant adults is typically used, but careful monitoring for efficacy and toxicity is recommended. No dose adjustment is recommended for hepatic or renal impairment in pregnancy as the drug is contraindicated in such conditions.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis. Avoid in children under 8 years and pregnant/breastfeeding women due to bone and tooth discoloration. Administer on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water to prevent esophagitis. Do not take with dairy, antacids, or iron supplements as they chelate and reduce absorption. Photosensitivity risk: advise sun avoidance and sunscreen use.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication on an empty stomach with a full glass of water.,Avoid dairy products, antacids, and iron supplements within 2 hours of taking this drug.,Use sunscreen and protective clothing to prevent severe sunburn.,Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction, severe headache, or vision changes immediately.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TETRACHEL vs ACEPHEN, answered by our medical review team.
TETRACHEL is a Tetracycline Antibiotic that works by Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TETRACHEL and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TETRACHEL is: 500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TETRACHEL and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TETRACHEL is classified as Category C. Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third tri. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.